Cargando…

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility

Several new multikinase inhibitors have recently been introduced into clinical practice for hepatocellular carcinoma (HCC) therapy. Small increases in survival were reported as well as considerable toxicity. There is thus a need for effective therapies with lower toxicities. We examined whether a co...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Alessandro, Rosalba, Refolo, Maria Grazia, Iacovazzi, Palma Aurelia, Pesole, Pasqua Letizia, Messa, Caterina, Carr, Brian Irving
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627995/
https://www.ncbi.nlm.nih.gov/pubmed/31181647
http://dx.doi.org/10.3390/cancers11060787
_version_ 1783434863584477184
author D’Alessandro, Rosalba
Refolo, Maria Grazia
Iacovazzi, Palma Aurelia
Pesole, Pasqua Letizia
Messa, Caterina
Carr, Brian Irving
author_facet D’Alessandro, Rosalba
Refolo, Maria Grazia
Iacovazzi, Palma Aurelia
Pesole, Pasqua Letizia
Messa, Caterina
Carr, Brian Irving
author_sort D’Alessandro, Rosalba
collection PubMed
description Several new multikinase inhibitors have recently been introduced into clinical practice for hepatocellular carcinoma (HCC) therapy. Small increases in survival were reported as well as considerable toxicity. There is thus a need for effective therapies with lower toxicities. We examined whether a combination of sorafenib and regorafenib might also be effective at very low concentrations, with resulting potential for lessened clinical toxicity. MTT test, clonogenic assay, Ki67 staining and cell cycle analysis were assessed for cell proliferation and Annexin V and western blotting analysis relative to the expression of cleaved Caspase-3 and BID for cell apoptosis. In these experimental conditions cell growth and migration were potently inhibited and apoptosis induced even in HCC cells producing high alpha fetoprotein (AFP) levels (clinically worse prognosis). The combination also inhibited levels of the two HCC biomarkers, AFP and des gamma carboxy prothrombin (DCP). Additional inhibition of Vascular Endothelial Growth Factor Receptor (VEGFR) or Insulin-like Growth Factor 1 Receptor (IGF1R) enhanced effects on AFP and DCP levels, cell growth inhibition and MAPK and PI3K/Akt signaling inhibition due to sorafenib/regorafenib combination. These combinations have the potential for decreased toxicity while simultaneously enhancing therapeutic effects. This potential decrease in toxicity is being explored in ongoing studies.
format Online
Article
Text
id pubmed-6627995
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-66279952019-07-23 Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility D’Alessandro, Rosalba Refolo, Maria Grazia Iacovazzi, Palma Aurelia Pesole, Pasqua Letizia Messa, Caterina Carr, Brian Irving Cancers (Basel) Article Several new multikinase inhibitors have recently been introduced into clinical practice for hepatocellular carcinoma (HCC) therapy. Small increases in survival were reported as well as considerable toxicity. There is thus a need for effective therapies with lower toxicities. We examined whether a combination of sorafenib and regorafenib might also be effective at very low concentrations, with resulting potential for lessened clinical toxicity. MTT test, clonogenic assay, Ki67 staining and cell cycle analysis were assessed for cell proliferation and Annexin V and western blotting analysis relative to the expression of cleaved Caspase-3 and BID for cell apoptosis. In these experimental conditions cell growth and migration were potently inhibited and apoptosis induced even in HCC cells producing high alpha fetoprotein (AFP) levels (clinically worse prognosis). The combination also inhibited levels of the two HCC biomarkers, AFP and des gamma carboxy prothrombin (DCP). Additional inhibition of Vascular Endothelial Growth Factor Receptor (VEGFR) or Insulin-like Growth Factor 1 Receptor (IGF1R) enhanced effects on AFP and DCP levels, cell growth inhibition and MAPK and PI3K/Akt signaling inhibition due to sorafenib/regorafenib combination. These combinations have the potential for decreased toxicity while simultaneously enhancing therapeutic effects. This potential decrease in toxicity is being explored in ongoing studies. MDPI 2019-06-07 /pmc/articles/PMC6627995/ /pubmed/31181647 http://dx.doi.org/10.3390/cancers11060787 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
D’Alessandro, Rosalba
Refolo, Maria Grazia
Iacovazzi, Palma Aurelia
Pesole, Pasqua Letizia
Messa, Caterina
Carr, Brian Irving
Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
title Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
title_full Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
title_fullStr Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
title_full_unstemmed Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
title_short Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
title_sort ramucirumab and gsk1838705a enhance the inhibitory effects of low concentration sorafenib and regorafenib combination on hcc cell growth and motility
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6627995/
https://www.ncbi.nlm.nih.gov/pubmed/31181647
http://dx.doi.org/10.3390/cancers11060787
work_keys_str_mv AT dalessandrorosalba ramucirumabandgsk1838705aenhancetheinhibitoryeffectsoflowconcentrationsorafenibandregorafenibcombinationonhcccellgrowthandmotility
AT refolomariagrazia ramucirumabandgsk1838705aenhancetheinhibitoryeffectsoflowconcentrationsorafenibandregorafenibcombinationonhcccellgrowthandmotility
AT iacovazzipalmaaurelia ramucirumabandgsk1838705aenhancetheinhibitoryeffectsoflowconcentrationsorafenibandregorafenibcombinationonhcccellgrowthandmotility
AT pesolepasqualetizia ramucirumabandgsk1838705aenhancetheinhibitoryeffectsoflowconcentrationsorafenibandregorafenibcombinationonhcccellgrowthandmotility
AT messacaterina ramucirumabandgsk1838705aenhancetheinhibitoryeffectsoflowconcentrationsorafenibandregorafenibcombinationonhcccellgrowthandmotility
AT carrbrianirving ramucirumabandgsk1838705aenhancetheinhibitoryeffectsoflowconcentrationsorafenibandregorafenibcombinationonhcccellgrowthandmotility